Neurogene Inc. (NGNE)
11.49
0.72 (6.69%)
At close: Apr 17, 2025, 3:59 PM
11.29
-1.73%
After-hours: Apr 17, 2025, 07:56 PM EDT
Company Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases.
Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease.
The company is headquartered in New York, New York.
Neurogene Inc.
| Country | United States |
| IPO Date | Mar 7, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Dr. Rachel L. McMinn Ph.D. |
Contact Details
Address: 535 W 24th Street New York, New York United States | |
| Website | https://www.neurogene.com |
Stock Details
| Ticker Symbol | NGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404644 |
| CUSIP Number | 64135M105 |
| ISIN Number | US64135M1053 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & Chief Executive Officer |
| Christine Mikail Cvijic J.D. | President, Chief Financial Officer & Corporate Secretary |
| Arvind Sreedharan | Senior Vice President of Business Operations |
| Donna M. Cochener-Metcalfe J.D. | Senior Vice President & General Counsel |
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control |
| Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical & Translational Research |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Ricardo Jimenez | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 424B3 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 24, 2025 | S-3 | Filing |
| Mar 24, 2025 | POS AM | Filing |
| Mar 24, 2025 | S-8 | Filing |
| Mar 24, 2025 | 8-K | Current Report |